You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NEWS / CORPORATE / .........

CORPORATE - 26-05-2016

SIPPET study results published in the “New England Journal of Medicine”

SIPPET Study results were published on May 26 by the prestigious “New England Journal of Medicine”.

SIPPET is the first randomized controlled multicenter study on hemophilia A and inhibitors development that answers the key clinical question on the role of the factor VIII product source. This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world. The study was sponsored by the Angelo Bianchi Bonomi Foundation, with financial support from the Italian Ministry of Health and unrestricted grants from Grifols, Kedrion and LFB.

Further information:
New England Journal of Medicine:

For more information please contact: